| Date |
Title |
| 02/23/10 |
Corcept Therapeutics Initiates a Phase 1 Study of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- CORT 108297 |
| 01/05/10 |
Corcept Therapeutics Announces Four Anticipated Milestones for 2010 |
| 11/10/09 |
Corcept Therapeutics Announces Recent Highlights and Third Quarter 2009 Financial Results |
| 10/13/09 |
Corcept Therapeutics Announces Pricing of Private Placement Cash Sufficient to Fund Company through Corlux NDA Submission |
| 08/11/09 |
Corcept Therapeutics Announces Second Quarter 2009 Results and Development Highlights |
| 05/11/09 |
Corcept Therapeutics Announces First Quarter 2009 Results and Development Highlights |
| 03/30/09 |
Corcept Therapeutics Announces Fourth Quarter and Full Year 2008 Results and Update on Development Programs |
| 02/23/09 |
Data Demonstrates Metabolic Benefits of Adding Corlux® to Treatment with Risperdal® |
| 02/02/09 |
Corlux Mitigates Weight Gain Associated with Risperdal Expands on Proof of Concept Established in Earlier Trials |
| 01/09/09 |
Trials Show Next-Generation GRII Receptor Antagonist Prevents and Reverses Weight Gain Associated with Use of Olanzapine - the Active Ingredient in Zyprexa® |
| 12/02/08 |
Caroline Loewy Joins Corcept as Chief Financial Officer |
| 11/13/08 |
Corcept Therapeutics Announces Third Quarter 2008 Results |
| 09/03/08 |
Corcept Therapeutics Continues Collaboration with Eli Lilly and Company |
| 08/13/08 |
Corcept Therapeutics Announces Second Quarter 2008 Results |
| 05/12/08 |
Corcept Therapeutics Announces First Quarter 2008 Results |
| 05/01/08 |
Corcept Therapeutics Announces Promising Results of Human Microdosing Study of Selective GR-II Antagonist |
| 03/27/08 |
Corcept Therapeutics Announces Fourth Quarter 2007 Results |
| 03/26/08 |
Corcept Therapeutics Completes $25 Million Private Equity Financing and Secures Committed Equity Financing Facility for up to $60 Million |
| 03/24/08 |
Corcept Therapeutics Announces Commencement of Next Phase 3 Study with Corlux for the Treatment of Psychotic Depression. Agreement Signed with MedAvante, Inc. |
| 03/17/08 |
Corcept
Therapeutics Announces $25.3 Million Private Equity Financing |
| 09/25/07 |
Corcept
Therapeutics Completes Second Closing Under August Private Equity
Financing Agreement |
| 09/11/07 |
Corcept
Therapeutics Receives FDA Notification Opening IND for Corlux®
for the Treatment of Cushing's Syndrome |
| 08/20/07 |
Corcept
Therapeutics Announces $10.1 Million Private Equity Financing |
| 08/13/07 |
Corcept
Therapeutics Announces Second Quarter 2007 Results |
| 07/25/07 |
Corcept
Therapeutics and Xceleron Sign Agreement for Microdosing Study
Using Accelerator Mass Spectrometry |
| 07/09/07 |
Corcept
Therapeutics Receives Orphan Drug Designation for Corlux®
Treatment of Cushing's Syndrome |
| 06/21/07 |
Corcept
Therapeutics Announces Positive Results from its Proof of Concept
Study Evaluating the Ability of CORLUX® to Mitigate Weight
Gain Associated
With Olanzapine |
| 05/14/07 |
Corcept
Therapeutics Announces First Quarter 2007 Results |
| 04/04/07 |
Nasdaq
Panel Grants Corcept Therapeutics' Request for Listing on the
Nasdaq Capital Market |
| 03/30/07 |
Corcept
Therapeutics Announces $9 Million Private Equity Financing |
| 03/28/07 |
Corcept
Therapeutics Announces Chief Financial Officer Resignation |
| 03/28/07 |
Corcept
Therapeutics Announces Fourth Quarter 2006 Results |
| 03/19/07 |
Corcept
Therapeutics Announces Phase 3 Study Evaluating Corlux for Psychotic
Major Depression Misses Primary Endpoint |
| 01/16/07 |
Corcept
Therapeutics Regains Compliance with Nasdaq Minimum Bid Price
Rule |
| 12/27/06 |
Corcept
Therapeutics Receives Nasdaq Notice of Non-Compliance. Company
Appeals to Nasdaq Listing Qualifications Panel |
| 12/15/06 |
Corcept
Therapeutics Completes $3 Million Private Equiity Financing |
| 11/17/06 |
Corcept
Therapeutics Receives Nasdaq Delisting Notification |
| 11/15/06 |
Corcept
Therapeutics Announces $3 Million Private Equity Financing |
| 11/13/06 |
Corcept
Therapeutics Completes Enrollment in Third Phase 3 Study for
Treating Psychotic Major Depression |
| 11/8/06 |
Corcept
Therapeutics Announces Third Quarter 2006 Results |
| 9/29/06 |
Corcept
Therapeutics Announces Negative Results from the Second of Three
Phase 3 Studies Evaluating Corlux® for Treating the Psychotic
Features of Psychotic Major Depression |
|
9/11/06 |
Corcept
Therapeutics to present at Merriman Curhan Ford 3rd Annual Investor
Summit on September 18, 2006 |
|
9/05/06 |
Corcept
Therapeutics to present at Bear Stearns 19th Annual Healthcare
Conference on September 12, 2006 |
|
8/30/06 |
Corcept
Therapeutics to present at Thomas Weisel Partners Healthcare
Conference on September 7, 2006 |
|
8/25/06 |
Corcept
Therapeutics Announces Negative Results from the First of Three
Phase 3 Studies Evaluating Corlux® for Treating the
Psychotic Features of Psychotic Major Depression |
|
8/10/06 |
Corcept
Therapeutics Announces Second Quarter 2006 Results |
|
8/7/06 |
Corcept
Therapeutics Announces Publication of Phase 2 Clinical Study
Results in the Journal of Biological Psychiatry |
|
7/7/06 |
Corcept
Therapeutics to Present at C.E. Unterberg, Towbin
Emerging Growth Conference on July 11, 2006 |
|
5/22/06 |
Corcept
Therapeutics Completes Enrollment in Second Phase 3 Study for
Treating Psychotic Major Depression |
|
5/09/06 |
Corcept
Therapeutics Announces First Quarter 2006 Results |
|
5/01/06 |
Corcept
Therapeutics Completes Enrollment in Phase 3 Study for Treating
Psychotic Major Depression |
|
3/08/06 |
Corcept
Therapeutics Announces Fourth Quarter 2005 Results |
|
2/06/06 |
Corcept
Therapeutics Announces Allowance of European Patent Covering
Use of GR-II Antagonists to Treat the Psychotic Features of
Psychotic Major Depression |
|
11/08/05 |
Corcept
Therapeutics Announces Third Quarter 2005 Results |
|
11/02/05 |
Corcept
Therapeutics to Present at Rodman & Renshaw Techvest 7th Annual
Healthcare Conference on November 9, 2005 |
|
10/21/05 |
Lilly
to Support Corcept's Clinical Study Evaluating the Ability of
a GR-II Antagonist to Mitigate the Weight Gain Associated with
Use of Atypical Antipsychotic Medications |
|
10/19/05 |
Corcept
Therapeutics to Present at C.E. Unterberg, Towbin
Emerging Growth Life Sciences Conference on October 26, 2005 |
|
09/26/05 |
Corcept
Announces Revised Reporting Dates for One of Its Three Phase III
Clinical Trials |
|
09/26/05 |
Corcept
Closes Enrollment of Proof of Concept Clinical Study Evaluating
Corlux® in Alzheimer's Disease |
|
08/31/05 |
Corcept
Therapeutics to Present at Thomas Weisel Partners Healthcare Conference
on September 7, 2005 |
|
08/9/05 |
Corcept
Therapeutics Announces Second Quarter 2005 Results |
|
06/8/05 |
Corcept
Therapeutics to Present at Thomas Weisel Partners Growth Forum
on June 13, 2005 |
|
05/11/05 |
Corcept
Therapeutics Announces First Quarter 2005 Results |
|
05/04/05 |
Corcept
Therapeutics Initiates Third Phase III Trial of Corlux® |
|
04/18/05 |
Corcept
Preclinical Trials Show Corlux® Prevents Weight Gain Associated
with Use of Olanzapine, the Active Ingredient in Zyprexa® |
|
03/03/05 |
Corcept
Therapeutics Announces Fourth Quarter 2004 Results |
|
02/22/05 |
Corcept
Therapeutics to Present at Wells Fargo Securities HealthCare Forum
on March 1, 2005 |
|
12/06/04 |
Corcept
Therapeutics to Present at Harris Nesbitt "Focus on Healthcare"
Investor Conference on December 8, 2004 |
| 10/28/04 |
Corcept
Therapeutics announces Third Quarter 2004 results |
| 10/26/04 |
Corcept
Therapeutics announces resolution of patent inventorship dispute
|
| 10/19/04 |
Corcept
Therapeutics commences second pivotal Phase III clinical trial
of Corlux |
| 10/12/04 |
Corcept
Therapeutics appoints James A. Harper to Board of Directors |
| 8/30/04 |
Corcept
Therapeutics receives special protocol assessment from FDA for
two pivotal Phase III trials of Corlux |
| 8/9/04 |
Corcept
Therapeutics announces Second Quarter Results |
| 7/26/04 |
Corcept
Therapeutics appoints David L. Mahoney to Board of Directors |
| 5/26/04 |
Corcept
Therapeutics announces First Quarter 2004 Results |
| 5/3/04 |
Corcept Therapeutics
presents results of clinical study at the 59th Annual Society
of Biological Psychiatry Conference |
| 4/14/04 |
Corcept Therapeutics announces Initial Public Offering |
| 2/10/04 |
Corcept Therapeutics files registration statement for Initial
Public Offering |
The documents
contained in this website include forward-looking statements (within
the meaning of the Private Securities Litigation Reform Act of 1995)
that involve substantial risks and uncertainties. All statements,
other than statements of historical facts, included on this web site
regarding our strategy, future operations, future financial position,
future revenues, projected costs, prospects, plans and objectives
of management are forward-looking statements. The words "anticipates,"
"believes," "estimates," "expects,"
"intends," "may," "plans," "projects,"
"will," "would" and similar expressions are intended
to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. We may not actually achieve
the plans, intentions or expectations disclosed in our forward-looking
statements and you should not place undue reliance on our forward-looking
statements. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in the forward-looking
statements we make. There are a number of important factors that could
cause Corcept's actual results to differ materially from those indicated
by such forward-looking statements. You should consult our Registration
on Form S-1 and subsequent reports filed with the SEC. We disclaim
any intention or obligation to update any forward-looking statements
as a result of developments occurring after the date any such statement
was first made.